194 related articles for article (PubMed ID: 29773902)
1. NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice.
Gabbasov R; Xiao F; Howe CG; Bickel LE; O'Brien SW; Benrubi D; Do TV; Zhou Y; Nicolas E; Cai KQ; Litwin S; Seo S; Golemis EA; Connolly DC
Oncogene; 2018 Aug; 37(35):4854-4870. PubMed ID: 29773902
[TBL] [Abstract][Full Text] [Related]
2. NEDD9 promotes lung cancer metastasis through epithelial-mesenchymal transition.
Jin Y; Li F; Zheng C; Wang Y; Fang Z; Guo C; Wang X; Liu H; Deng L; Li C; Wang H; Chen H; Feng Y; Ji H
Int J Cancer; 2014 May; 134(10):2294-304. PubMed ID: 24174333
[TBL] [Abstract][Full Text] [Related]
3. NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer.
Kong C; Wang C; Wang L; Ma M; Niu C; Sun X; Du J; Dong Z; Zhu S; Lu J; Huang B
PLoS One; 2011; 6(7):e22666. PubMed ID: 21829474
[TBL] [Abstract][Full Text] [Related]
4. Involvement of NEDD9 in the invasion and migration of gastric cancer.
Feng J; Zhao J; Xie H; Yin Y; Luo G; Zhang J; Feng Y; Li Z
Tumour Biol; 2015 May; 36(5):3621-8. PubMed ID: 25577245
[TBL] [Abstract][Full Text] [Related]
5. The metastasis gene NEDD9 product acts through integrin β3 and Src to promote mesenchymal motility and inhibit amoeboid motility.
Ahn J; Sanz-Moreno V; Marshall CJ
J Cell Sci; 2012 Apr; 125(Pt 7):1814-26. PubMed ID: 22328516
[TBL] [Abstract][Full Text] [Related]
6. Dual Targeting of Mesenchymal and Amoeboid Motility Hinders Metastatic Behavior.
Jones BC; Kelley LC; Loskutov YV; Marinak KM; Kozyreva VK; Smolkin MB; Pugacheva EN
Mol Cancer Res; 2017 Jun; 15(6):670-682. PubMed ID: 28235899
[TBL] [Abstract][Full Text] [Related]
7. Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human lung cancer.
Kondo S; Iwata S; Yamada T; Inoue Y; Ichihara H; Kichikawa Y; Katayose T; Souta-Kuribara A; Yamazaki H; Hosono O; Kawasaki H; Tanaka H; Hayashi Y; Sakamoto M; Kamiya K; Dang NH; Morimoto C
Clin Cancer Res; 2012 Nov; 18(22):6326-38. PubMed ID: 23037767
[TBL] [Abstract][Full Text] [Related]
8. SOX9 is a dose-dependent metastatic fate determinant in melanoma.
Yang X; Liang R; Liu C; Liu JA; Cheung MPL; Liu X; Man OY; Guan XY; Lung HL; Cheung M
J Exp Clin Cancer Res; 2019 Jan; 38(1):17. PubMed ID: 30642390
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of NEDD9 is associated with altered expression of E-Cadherin, β-Catenin and N-Cadherin and predictive of poor prognosis in non-small cell lung cancer.
Miao Y; Li AL; Wang L; Fan CF; Zhang XP; Xu HT; Yang LH; Liu Y; Wang EH
Pathol Oncol Res; 2013 Apr; 19(2):281-6. PubMed ID: 23086683
[TBL] [Abstract][Full Text] [Related]
10. NEDD9 may regulate hepatocellular carcinoma cell metastasis by promoting epithelial-mesenchymal-transition and stemness via repressing Smad7.
Wang Z; Shen M; Lu P; Li X; Zhu S; Yue S
Oncotarget; 2017 Jan; 8(1):1714-1724. PubMed ID: 27974675
[TBL] [Abstract][Full Text] [Related]
11. Wilms' tumor 1 (
Han Y; Song C; Zhang T; Zhou Q; Zhang X; Wang J; Xu B; Zhang X; Liu X; Ying X
Cell Cycle; 2020 Oct; 19(20):2662-2675. PubMed ID: 32892698
[TBL] [Abstract][Full Text] [Related]
12. The overexpression of scaffolding protein NEDD9 promotes migration and invasion in cervical cancer via tyrosine phosphorylated FAK and SRC.
Sima N; Cheng X; Ye F; Ma D; Xie X; Lü W
PLoS One; 2013; 8(9):e74594. PubMed ID: 24058594
[TBL] [Abstract][Full Text] [Related]
13. NEDD9 promotes oncogenic signaling in mammary tumor development.
Izumchenko E; Singh MK; Plotnikova OV; Tikhmyanova N; Little JL; Serebriiskii IG; Seo S; Kurokawa M; Egleston BL; Klein-Szanto A; Pugacheva EN; Hardy RR; Wolfson M; Connolly DC; Golemis EA
Cancer Res; 2009 Sep; 69(18):7198-206. PubMed ID: 19738060
[TBL] [Abstract][Full Text] [Related]
14. NEDD9 overexpression is associated with the progression of and an unfavorable prognosis in epithelial ovarian cancer.
Wang H; Mu X; Zhou S; Zhang J; Dai J; Tang L; Xiao L; Duan Z; Jia L; Chen S
Hum Pathol; 2014 Feb; 45(2):401-8. PubMed ID: 24439227
[TBL] [Abstract][Full Text] [Related]
15. Roles of neural precursor cell expressed, developmentally downregulated 9 in tumor-associated cellular processes (Review).
Zhang S; Wu L
Mol Med Rep; 2015 Nov; 12(5):6415-21. PubMed ID: 26324022
[TBL] [Abstract][Full Text] [Related]
16. [Knockdown of NEDD9 inhibits the proliferation, invasion and migration of esophageal carcinoma EC109 cells].
Zhang W; Li S; Zhao Y; Guo N; Li Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Dec; 32(12):1662-1666. PubMed ID: 27916098
[TBL] [Abstract][Full Text] [Related]
17. Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases.
Shagisultanova E; Gaponova AV; Gabbasov R; Nicolas E; Golemis EA
Gene; 2015 Aug; 567(1):1-11. PubMed ID: 25967390
[TBL] [Abstract][Full Text] [Related]
18. Effects of lentivirus-mediated RNAi knockdown of NEDD9 on human lung adenocarcinoma cells in vitro and in vivo.
Chang JX; Gao F; Zhao GQ; Zhang GJ
Oncol Rep; 2014 Oct; 32(4):1543-9. PubMed ID: 25051398
[TBL] [Abstract][Full Text] [Related]
19. The CRTC1-NEDD9 signaling axis mediates lung cancer progression caused by LKB1 loss.
Feng Y; Wang Y; Wang Z; Fang Z; Li F; Gao Y; Liu H; Xiao T; Li F; Zhou Y; Zhai Q; Liu X; Sun Y; Bardeesy N; Wong KK; Chen H; Xiong ZQ; Ji H
Cancer Res; 2012 Dec; 72(24):6502-11. PubMed ID: 23074285
[TBL] [Abstract][Full Text] [Related]
20. NEDD9 regulates actin dynamics through cortactin deacetylation in an AURKA/HDAC6-dependent manner.
Kozyreva VK; McLaughlin SL; Livengood RH; Calkins RA; Kelley LC; Rajulapati A; Ice RJ; Smolkin MB; Weed SA; Pugacheva EN
Mol Cancer Res; 2014 May; 12(5):681-93. PubMed ID: 24574519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
